Pediatrik Ewing Sarkoma Hastalarının Multimodal Tedavisinde Adjuvan Radyoterapi

Abstract

Aim: This study aimed to report the adjuvant radiotherapy results of pediatric patients with Ewing sarcoma who received multimodal treatment for this rare disease using modern radiotherapy (RT) techniques.
 Material and Methods: Pediatric patients with Ewing Sarcoma (ES) who received adjuvant radiotherapy were evaluated retrospectively. The study’s primary endpoint was overall survival (OS) and disease-free survival (DFS). The secondary endpoint was local relapse-free survival after RT (LRFS- RT) and overall survival after RT (OS-RT).
 Results: The results of 18 pediatric patients diagnosed with Ewing Sarcoma in our clinic between 09.12.2013-04.04.2021 and underwent RT for adjuvant were evaluated retrospectively. The three patients were excluded since they did not meet the inclusion criteria. The median age of the patients at the time of diagnosis was 10.5 (range 3-17). The time from diagnosis to the onset of RT was 8.6 (range 2-20) months. The median fraction dose was 180 cGy, and the median total RT dose was 50.4 (range 45-55.80) Gy. The median follow-up period of the study was 27 (range 11-86) months. The 12 (80%) patients survived, and 3 (20%) died. The median OS diagnosis of the patients was 27.3 (range 11 to 86.5) months. The overall survival of the patients after RT was median 17.3 (range 4.4-83.9) months. Recurrence (local+distant) was observed in 7 patients (46.7%); 2 (13.3%) local, 3 (20%) distant and 2 (13.3%) both. The median DFS was 24 months (range 1-86.5). Median LRFS-RT is 14.2 (range 1-83.9) months. The relationship between LRFS-RT and age (